Outcomes in men with large prostates (≥ 60 cm3) treated with definitive proton therapy for prostate cancer

Acta Oncologica

Volumn 52, Issue 3, 2013, Pages 470-476

  McGee, Lisa ^a   Mendenhall, Nancy P ^a,b   Henderson, Randal H ^b   Morris, Christopher G ^a,b   Nichols, Romaine C ^b   Marcus, Robert J ^a,b   Li, Zuofeng ^b   Mendenhall, William M ^a   Williams, Christopher R ^b   Hoppe, Bradford S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DUTASTERIDE; FINASTERIDE; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ABDOMINAL CRAMP; ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BALLOON DILATATION; BLADDER CATHETERIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER SURGERY; CAUTERIZATION; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HYPERBARIC OXYGEN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SIZE; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SABAL; TRANSURETHRAL RESECTION; URETHRA STRICTURE; URINE INCONTINENCE; UROGENITAL TRACT DISEASE;

EID: 84875152555     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.744467     Document Type: Article

References (20)

1. Harsolia A , Vargas C, Y an D, B rabbins D, L ockman D, L iang J, et al . Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: Dose-volume analysis of a phase II dose-escalation study . Int J Radiat Oncol Biol Phys 2007 ; 69 : 1100-9 (Pubitemid 47625853)
2. Pal RP, B hatt JR, K han MA, D uggleby S, C amilleri P, Bell CR, et al . Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy . Brachytherapy 2011; 10 : 107-16
3. Levinson A W, W ard NT, S ulman A, M ettee LZ, L ink RE, Su LM, et al . The impact of prostate size on perioperative outcomes in a large laparoscopic radical prostatectomy series . J Endourol 2009; 23 : 147-52
4. Zelefsky MJ, L yass O, F uks Z, W olfe T, B urman C, L ing CC, et al . Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy . J Clin Oncol 1998; 16 : 3380-5 (Pubitemid 28481636)
5. Zelefsky MJ, H arrison A. N eoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy . Urology 1997; 49 : 38-45 (Pubitemid 27133509)
6. Sanda MG, D unn RL, M ichalski J, S andler HM, N orthouse L, Hembroff L, et al . Quality of life and satisfaction with outcome among prostate-cancer survivors . N Engl J Med 2008; 358 : 1250-61 (Pubitemid 351439226)
7. Nanda A, C hen MH, B raccioforte MH, M oran BJ, D 'Amico AV . Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction . JAMA 2009; 302 : 866-73
8. Vargas C, F ryer A, M ahajan C, I ndelicato D, H orne D, Chellini A, et al . Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer . Int J Radiat Oncol Biol Phys 2008; 70 : 744-51
9. Mendenhall N P, Li Z, Hoppe B S, Marcus R B, Jr., Mendenhall WM, Nichols RC, et al . Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer . Int J Radiat Oncol Biol Phys 2012; 82 : 213-21
10. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute: Cancer Therapy Evaluation Program; 2006 [updated March 4, 2007]; Available from: Http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
11. Roach M, 3rd, H anks G, T hames H, Jr., S chellhammer P, Shipley WU, Sokol GH, et al . Defi ning biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendanot a contributing factor. tions of the RTOG-ASTRO Phoenix Consensus Conference . Int J Radiat Oncol Biol Phys 2006 ; 65 : 965-74
12. Aizer AA, Anderson [12] N S, O h S C, Y u J B, M cKeon AM, D ecker RH, et al . The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy . Int J Radiat Oncol Biol Phys 2011; 79 : 379-84
13. Monroe AT, F aricy P O, J ennings S B, B iggers R D, G ibbs G L, Peddada AV . High-dose-rate brachytherapy for large prostate volumes (- or - 50cc)-Uncompromised dosimetric coverage and acceptable toxicity . Brachytherapy 2008; 7 : 7-11
14. Pinkawa M, F ischedick K, A sadpour B, G agel B, P iroth MD, Nussen S, et al . Toxicity profi le with a large prostate volume after external beam radiotherapy for localized prostate cancer . Int J Radiat Oncol Biol Phys 2008; 70 : 83-9
15. Forman JD, K eole S, B olton S, T ekyi-Mensah S. A ssociation of prostate size with urinary morbidity following mixed conformal neutron and photon irradiation . Int J Radiat Oncol Biol Phys 1999; 45 : 871-5 (Pubitemid 29525449)
16. Sandhu A S, Z elefsky MJ, L ee HJ, L ombardi D, F uks Z, Leibel SA . Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection . Int J Radiat Oncol Biol Phys 2000; 48 : 643-7
17. Singer PA, T asch ES, S tocking C, R ubin S, S iegler M, Weichselbaum R . Sex or survival: Trade-offs between quality and quantity of life . J Clin Oncol 1991; 9 : 328-34
18. Dacal K, S ereika S M, G reenspan S L. Q uality of life in prostate cancer patients taking androgen deprivation therapy . J Am Geriatr Soc 2006; 54 : 85-90
19. Isbarn H, B occon-Gibod L, C arroll PR, M ontorsi F, Schulman C, Smith MR, et al . Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefi ts and risks . Eur Urol 2009; 55 : 62-75
20. Sevilla C, M aliski SL, K wan L, C onnor SE, L itwin MS . Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy . Prostate Cancer Prostatic Dis 2012; 15 : 237-43